HIGHLIGHTS
SUMMARY
Since the consolidation of the chemoradiotherapy with mitomycin and fluoropyrimidine as a standard treatment for localized disease, no clear advances have been achieved for several decades, and the disease remained out of the focus of the development of breakthrough strategies, partly due to its low incidence, especially at advanced stages. In chemorefractory patients, several prospective trials evaluated PD-1/L1 inhibitors as monotherapy in advanced SCCA, refractory to at least one line of systemic treatment. VolaTIL trial (NCT) is a phase II clinical trial aiming at improving the anti-PD1/PDL1 efficacy by using . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.